Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT06271577

Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II

Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT06271577.

📅 09 Apr 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT06271577
Start
2024-03-12
Completion
2026-12
ClinicaliQ Trial Snapshot
  • Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT06271577.
  • Smartphone 12-lead ECG device tested against standard machines for accurately diagnosing heart attacks in emergency settings.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

AliveCor (www.alivecor.com) has developed several electrocardiogram (ECG) devices that interface with iOS and Android smartphones and tablets via various Kardia apps. The current Kardia family of devices can measure single lead and six limb-lead ECGs, depending on the device. KardiaMobile, KardiaMobile 6L, and KardiaMobile Card have FDA clearance for ECG rhythm recording. A modified single-lead Kardia smartphone 12-lead ECG was previously validated in the multicenter ST LEUIS study for the diagnosis of ST-Segment Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI). Recently, AliveCor developed a new device: AliveCor (AC)…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →
Clinical Brief
Man completes half marathon after two heart attacks
Cardiology / Cardiovascular · BBC Health · 26 Aug 2026
Key Takeaways for Clinical Practice Cardiac rehabilitation and secondary prevention can enable significant functional recovery post-myocardial infarction, with patients potentially returning to…
View brief →
Clinical Brief
How Eriksen’s heart device kicked into action
Cardiology / Cardiovascular · BBC Health · 08 Jun 2026
An ICD (implantable cardioverter-defibrillator) successfully detected and treated a life-threatening cardiac arrhythmia in the collapsed footballer, demonstrating the device's critical role in…
View brief →
Clinical Brief
How Eriksen’s heart device kicked into action
Cardiology / Cardiovascular · BBC Health · 08 Jun 2026
Christian Eriksen's implanted cardioverter-defibrillator (ICD) functioned appropriately during his on-pitch cardiac arrest, demonstrating effective device intervention in a real-world emergency scenario The…
View brief →
Guideline
Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction
Cardiology / Cardiovascular · 05 Aug 2026
Finerenone is recommended as an option for chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) and can be initiated…
View guideline →
Guideline
Empagliflozin for Treating Chronic Heart Failure with Reduced Ejection Fraction (NICE TA773)
Cardiology / Cardiovascular · 27 Mar 2026
Initiate empagliflozin 10 mg once daily as add-on therapy to standard HFrEF treatment (ACE inhibitors, beta-blockers, and aldosterone antagonists) in adults with…
View guideline →